Apricus Biosciences, Inc., a biopharmaceutical company, focuses on the development of product candidates in the areas of urology and rheumatology. The company develops Vitaros, a topically-applied cream formulation of alprostadil used for the treatment of erectile dysfunction; and RayVa, which is in Phase IIa clinical trial to treat Raynaud's phenomenon associated with scleroderma. It has a license and stock issuance agreement with Forendo Pharma Ltd. to develop and commercialize fispemifene, a tissue-specific selective estrogen receptor modulator to treat symptomatic secondary hypogonadism, chronic prostatitis, and lower urinary tract symptoms in men. Apricus Biosciences, Inc. operates in Europe, Canada, Latin America, and the Asia Pacific. The company was formerly known as NexMed, Inc. and changed its name to Apricus Biosciences, Inc. in September 2010. Apricus Biosciences, Inc. was founded in 1987 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APRI
CUSIPN/A
Phone858-222-8041
Debt
Debt-to-Equity RatioN/A
Current Ratio3.75
Quick Ratio3.75
Price-To-Earnings
Trailing P/E Ratio-0.31
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.76 million
Price / Sales1.26
Cash FlowN/A
Price / CashN/A
Book Value$0.29 per share
Price / Book1.07
Profitability
EPS (Most Recent Fiscal Year)($0.99)
Net Income$320,000.00
Net MarginsN/A
Return on Equity-216.07%
Return on Assets-152.06%
Miscellaneous
Employees11
Outstanding Shares23,440,000
Market Cap$7.27 million
Apricus Biosciences (NASDAQ:APRI) Frequently Asked Questions
What is Apricus Biosciences' stock symbol?
Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."
How were Apricus Biosciences' earnings last quarter?
Apricus Biosciences Inc (NASDAQ:APRI) issued its quarterly earnings results on Thursday, August, 9th. The company reported ($0.10) EPS for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.04. View Apricus Biosciences' Earnings History.
When is Apricus Biosciences' next earnings date?
What price target have analysts set for APRI?
1 brokers have issued 12-month price objectives for Apricus Biosciences' shares. Their predictions range from $1.00 to $1.00. On average, they anticipate Apricus Biosciences' stock price to reach $1.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price. View Analyst Price Targets for Apricus Biosciences.
What is the consensus analysts' recommendation for Apricus Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apricus Biosciences in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apricus Biosciences.
Are investors shorting Apricus Biosciences?
Apricus Biosciences saw a decline in short interest in September. As of September 28th, there was short interest totalling 1,041,203 shares, a decline of 29.4% from the September 14th total of 1,474,242 shares. Based on an average daily trading volume, of 426,171 shares, the days-to-cover ratio is currently 2.4 days. Approximately 4.6% of the shares of the company are sold short. View Apricus Biosciences' Current Options Chain.
Who are some of Apricus Biosciences' key competitors?
Some companies that are related to Apricus Biosciences include AEterna Zentaris (AEZS), Citius Pharmaceuticals (CTXR), Sernova (SEOVF), KITOV PHARMA LT/S (KTOV), Provectus Biopharmaceuticals (PVCT), Xenetic Biosciences (XBIO), vTv Therapeutics (VTVT), BENITEC BIOPHAR/S (BNTC), OvaScience (OVAS), Edge Therapeutics (EDGE), NeuroVive Pharmaceutical (NEVPF), Innovus Pharmaceuticals (INNV), Nuvo Pharmaceuticals (NRIFF), Fibrocell Science (FCSC) and RegeneRx Biopharmaceuticals (RGRX).
Who are Apricus Biosciences' key executives?
Apricus Biosciences' management team includes the folowing people:
- Mr. Richard W. Pascoe, CEO, CFO, Sec., Principal Accounting Officer & Director (Age 54)
- Mr. Brian T. Dorsey, Sr. VP & Chief Devel. Officer (Age 49)
- Mr. Neil C. Morton, Sr. VP & Chief Bus. Officer (Age 42)
- Ms. Kelly Deck, Exec. Director of Fin.
- Ms. Mary Naggs, VP & Gen. Counsel
How do I buy shares of Apricus Biosciences?
Shares of APRI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apricus Biosciences' stock price today?
One share of APRI stock can currently be purchased for approximately $0.31.
How big of a company is Apricus Biosciences?
Apricus Biosciences has a market capitalization of $7.27 million and generates $5.76 million in revenue each year. The company earns $320,000.00 in net income (profit) each year or ($0.99) on an earnings per share basis. Apricus Biosciences employs 11 workers across the globe.
What is Apricus Biosciences' official website?
How can I contact Apricus Biosciences?
Apricus Biosciences' mailing address is 11975 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The company can be reached via phone at 858-222-8041 or via email at [email protected]
MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe APRI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APRI will underperform the S&P 500 over the long term. You may vote once every thirty days.
